GSK (LON:GSK) Releases Quarterly Earnings Results

Key Points

• GSK reported a quarterly earnings per share (EPS) of GBX 75.30 ($1.01) with a return on equity of 18.08% and a net margin of 8.02%.
• Following the earnings announcement, GSK shares increased by 4.7%, reaching a price of GBX 1,462.50 ($19.53) with a market capitalization of £59.35 billion.
• Research analysts have varied ratings on GSK, with target prices ranging from GBX 1,450 ($19.36) to GBX 2,000 ($26.71) based on recent evaluations.

GSK (LON:GSK - Get Free Report) issued its earnings results on Wednesday. The company reported GBX 75.30 ($1.00) earnings per share (EPS) for the quarter, Digital Look Earnings reports. GSK had a net margin of 8.02% and a return on equity of 18.08%.

GSK Stock Performance

GSK traded down GBX 21.50 ($0.29) on Friday, reaching GBX 1,396.50 ($18.54). The stock had a trading volume of 8,559,338 shares, compared to its average volume of 13,407,056. GSK has a 12-month low of GBX 1,242.50 ($16.49) and a 12-month high of GBX 1,678.68 ($22.28). The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The business's 50-day moving average price is GBX 1,434.66 and its two-hundred day moving average price is GBX 1,426.11. The company has a market cap of £56.67 billion, a P/E ratio of 22.56, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

Analysts Set New Price Targets

Several research analysts recently issued reports on GSK shares. Shore Capital reissued a "buy" rating and set a GBX 2,000 ($26.55) target price on shares of GSK in a report on Wednesday. Berenberg Bank reissued a "hold" rating and set a GBX 1,600 ($21.24) target price on shares of GSK in a report on Friday, July 18th. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a report on Friday, July 18th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a GBX 1,450 ($19.25) price objective on shares of GSK in a report on Thursday.

Insider Buying and Selling at GSK

In other GSK news, insider Emma Walmsley sold 5,473 shares of GSK stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.23), for a total value of £79,303.77 ($105,261.18). Also, insider Jonathan Symonds acquired 1,350 shares of the business's stock in a transaction on Friday, June 20th. The stock was purchased at an average cost of GBX 1,435 ($19.05) per share, with a total value of £19,372.50 ($25,713.43). Over the last quarter, insiders bought 1,905 shares of company stock valued at $2,732,835. Corporate insiders own 1.61% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.